BCDA BioCardia
BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular and respiratory disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company's biotherapeutic platforms in clinical development. The Company's products include the Helix Biotherapeutic Delivery System and its steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix system and clinical support for their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia, and acute myocardial infarction.
Company profile
Ticker
BCDA, BCDAW
Exchange
Website
CEO
Peter Altman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Denali Therapeutics • Seagen ...
Former names
Cardo Medical, Inc., CLICKNSETTLE COM INC, NAM CORP, Tiger X Medical, Inc.
SEC CIK
Corporate docs
IRS number
232753988
BCDA stock data
()
News
BioCardia Announces Japanese Patent On Imaging System For Targeting Cardiac Therapies
15 Jul 21
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
6 Jul 21
BioCardia Reports Completion Of Fourth Data Safety Monitoring Board Review For Its CardiAMP Cell Therapy Heart Failure Trial; DSMB Indicated No Safety Concerns, Recommended Study Continue As Designed
23 Jun 21
BioCardia To Present CardiAMP Cell Therapy Clinical Trial Data At European Society Of Cardiology Heart Failure 2021
22 Jun 21
BioCardia Reports European Patent Office Decision To Grant Patent On Autologous Cell Therapy Patient Selection Diagnostic Assay
21 Jun 21
Investment data
Securities sold
Number of investors
Calendar
13 May 21
29 Jul 21
31 Dec 21
Financial summary
Quarter (USD) |
Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from BioCardia earnings reports.
| Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 21.5M | 21.5M | 21.5M | 21.5M | 21.5M | 21.5M |
| Cash burn (monthly) | (positive/no burn) | (positive/no burn) | 990.67K | 1.16M | 627.67K | 937.25K |
| Cash used (since last report) | n/a | n/a | 3.92M | 4.58M | 2.48M | 3.71M |
| Cash remaining | n/a | n/a | 17.58M | 16.92M | 19.02M | 17.79M |
| Runway (months of cash) | n/a | n/a | 17.7 | 14.6 | 30.3 | 19.0 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 15 Jun 21 | Allen Jim L. | Stock Option Common stock | Grant | Aquire A | No | No | 4.43 | 12,434 | 55.08K | 12,434 |
| 15 Jun 21 | Moyes Jay M | Stock Option Common stock | Grant | Aquire A | No | No | 4.43 | 12,434 | 55.08K | 16,355 |
| 15 Jun 21 | Stertzer Simon H | Stock Option Common stock | Grant | Aquire A | No | No | 4.43 | 12,434 | 55.08K | 22,642 |
| 15 Jun 21 | Krasno Richard M | Stock Option Common stock | Grant | Aquire A | No | No | 4.43 | 12,434 | 55.08K | 12,434 |
| 15 Jun 21 | Blank Andrew Scott | Stock Option Common stock | Grant | Aquire A | No | No | 4.43 | 12,434 | 55.08K | 12,434 |
Institutional ownership Q1 2021
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
13F holders |
Current |
|---|---|
| Total holders | 0 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
13F shares |
Current |
|---|---|
| Total value | 0 |
| Total shares | 0 |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|
Financial report summary
?Competition
Abbott Laboratories • Caladrius Biosciences • Gene Biotherapeutics • ThermoGenesis • Vericel • Plus Therapeutics • Capricor Therapeutics • Mesoblast • Athersys • VistaGen TherapeuticsContent analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
Accelerated, Additionally, agent, announced, announcing, aware, begun, beneficially, biotechnology, brought, Cap, confidential, create, difficult, directly, discretion, duration, economy, elevated, evolve, exceed, February, fee, FESC, geography, highly, hold, inconsistent, indirectly, Japanese, larger, lesser, Lincoln, maximum, meet, Meeting, mutate, mutually, negotiate, outbreak, Park, partnership, pay, percentage, population, pro, proxy, rata, recognition, registered, Regular, supply, thereunder, timeline, transseptal, upper, variation
Removed:
absent, accurately, acquired, adequate, administered, Aid, alleviate, allogenic, anatomy, annum, assessed, assign, assigned, assignment, assistance, back, Bank, bankruptcy, belonged, Borrower, building, cardiomyopathy, care, carried, cease, Chhabria, commercialize, commercially, complaint, complex, conduction, confidence, converted, correction, customary, customize, decline, deducting, default, delay, depending, detail, disbursed, disbursement, discovery, dissolution, DNA, documentation, doubt, ejection, enable, enacted, endpoint, estimated, evidencing, exercised, expired, external, facility, firm, forced, forecasted, formalized, founded, fourth, fraction, futility, generating, guidance, guide, historic, hypertrophic, impacted, Incentive, indirect, Industry, infarction, institutional, introducer, invention, inventorship, investor, involved, involving, judge, July, lack, Lender, letter, lifted, liquidate, listing, loan, Mark, maturity, member, merger, misappropriated, misappropriation, misstated, monthly, Nasdaq, navigate, neurokinin, NOL, obstructive, occur, occurring, October, order, ordinary, par, patent, payable, Paycheck, payroll, pending, perform, performing, positioned, PPP, preceding, preliminary, prepaid, prepayment, preserved, presiding, proceeding, Program, promissory, Protection, protocol, qualified, qualifying, raw, readout, realized, reassigned, reflected, refund, Relief, remediate, representative, request, reserve, resolve, resource, response, restricted, resumption, reverse, reviewed, reviewing, rightfully, robust, satisfaction, scenario, scrap, Security, senior, September, shape, shrinkage, Silicon, small, split, stated, steerable, stellar, submitted, subsequently, substantial, sum, technical, thousand, trade, transition, unavoidable, uncertainty, underwriting, underwritten, unregistered, unremediated, unsecured, usage, utility, Valley, viable, Vincent, volatility, wholly, worsening, write
Financial reports
10-Q
2021 Q1
Quarterly report
13 May 21
10-K
2020 FY
Annual report
30 Mar 21
10-Q
2020 Q3
Quarterly report
10 Nov 20
10-Q
2020 Q2
Quarterly report
13 Aug 20
10-Q
2020 Q1
Quarterly report
15 May 20
10-K
2019 FY
Annual report
9 Apr 20
NT 10-K
Notice of late annual filing
31 Mar 20
10-Q
2019 Q3
Quarterly report
19 Nov 19
NT 10-Q
Notice of late quarterly filing
15 Nov 19
10-Q
2019 Q2
Quarterly report
13 Aug 19
Current reports
8-K
BioCardia Announces Japanese Patent on Imaging System for Targeting Cardiac Therapies
15 Jul 21
8-K
Regulation FD Disclosure
23 Jun 21
8-K
BioCardia to Present CardiAMP Cell Therapy Clinical Trial Data at European Society of Cardiology Heart Failure 2021
22 Jun 21
8-K
BioCardia Announces European Patent Office Decision to Grant Patent on Autologous Cell Therapy Patient Selection Diagnostic Assay
21 Jun 21
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 21
8-K
BioCardia to Be Added to the Russell Microcap® Index
14 Jun 21
8-K
Biocardia Reports First Quarter 2021 Financial Results and Business Highlights
13 May 21
8-K
Departure of Directors or Certain Officers
27 Apr 21
8-K
BioCardia Signs Agreement with Leading Japanese Biotechnology Company for Catheter Biotherapeutic Delivery Product Candidates
26 Apr 21
8-K
Other Events
30 Mar 21
Registration and prospectus
S-8
Registration of securities for employees
30 Mar 21
424B5
Prospectus supplement for primary offering
29 Mar 21
424B5
Prospectus supplement for primary offering
16 Dec 20
424B5
Prospectus supplement for primary offering
15 Dec 20
S-3
Shelf registration
9 Oct 20
424B4
Prospectus supplement with pricing info
18 Jun 20
S-1/A
IPO registration (amended)
15 Jun 20
FWP
Free writing prospectus
8 Jun 20
S-1/A
IPO registration (amended)
22 May 20
POS AM
Prospectus update (post-effective amendment)
19 Apr 20
Proxies
DEFA14A
Additional proxy soliciting materials
30 Apr 21
DEF 14A
Definitive proxy
30 Apr 21
DEF 14A
Definitive proxy
1 Dec 20
PRE 14A
Preliminary proxy
20 Nov 20
DEFA14A
Additional proxy soliciting materials
15 Oct 19
DEF 14A
Definitive proxy
15 Oct 19
PRE 14A
Preliminary proxy
4 Oct 19
DEF 14C
Information statement
16 Apr 19
PRE 14C
Preliminary information
5 Apr 19
DEF 14A
Definitive proxy
27 Apr 18
Other
EFFECT
Notice of effectiveness
21 Oct 20
CORRESP
Correspondence with SEC
18 Oct 20
UPLOAD
Letter from SEC
14 Oct 20
EFFECT
Notice of effectiveness
17 Jun 20
CORRESP
Correspondence with SEC
14 Jun 20
CORRESP
Correspondence with SEC
14 Jun 20
EFFECT
Notice of effectiveness
22 Apr 20
UPLOAD
Letter from SEC
19 Feb 20
UPLOAD
Letter from SEC
16 Dec 19
CORRESP
Correspondence with SEC
4 Dec 19
Ownership
SC 13G
BioCardia / Francis Capital Management ownership change
21 Jun 21
4
BioCardia / KRISZTINA M ZSEBO ownership change
15 Jun 21
4
BioCardia / SIMON H STERTZER ownership change
15 Jun 21
4
BioCardia / RICHARD M KRASNO ownership change
15 Jun 21
4
BioCardia / Andrew Scott Blank ownership change
15 Jun 21
4
BioCardia / Jim L. Allen ownership change
15 Jun 21
4
BioCardia / JAY M MOYES ownership change
15 Jun 21
4
BioCardia / Peter Altman ownership change
11 Jun 21
4
BioCardia / David McClung ownership change
11 Jun 21
4
BioCardia / EDWARD M GILLIS ownership change
11 Jun 21
Patents
APP
Utility
Methods of Measuring Potential for Therapeutic Potency and Defining Dosages for Autologous Cell Therapies
3 Jun 21
Autologous bone marrow cells (BMC) are transplanted to a heterologous site in a patient after a sample of the patient's BMC has been tested and found to have a phenotypic profile which meets minimum criteria for transplantation.
GRANT
Utility
Devices and methods for accessing the vasculature of a patient
28 Dec 20
A steerable guide sheath system adapted for delivery into a patient's vasculature.
APP
Utility
Radial and Trans-endocardial Delivery Catheter
23 Dec 20
A needle-injection catheter includes a catheter body having a distal end, a proximal end, a stiff proximal portion, a flexible distal portion, and a delivery lumen extending therethrough.
GRANT
Utility
Radial and trans-endocardial delivery catheter
21 Sep 20
A needle-injection catheter includes a catheter body having a distal end, a proximal end, a stiff proximal portion, a flexible distal portion, and a delivery lumen extending therethrough.
GRANT
Utility
Drug delivery catheters that attach to tissue and methods for their use
27 Apr 20
A system and method for delivering a drug to a target site within a patient's body.